Literature DB >> 32163911

Genetic profile of advanced thyroid cancers in relation to distant metastasis.

Eyun Song1, Dong Eun Song2, Jonghwa Ahn1, Tae Yong Kim1, Won Bae Kim1, Young Kee Shong1, Min Ji Jeon1, Won Gu Kim1.   

Abstract

Major clinical challenges exist with differentiated thyroid cancers with distant metastases or rare but aggressive types, such as poorly differentiated thyroid carcinomas and anaplastic thyroid carcinomas. The precise characterization of the mutational profile in these advanced thyroid cancers is crucial. Samples were collected from primary tumors and distant metastases of 64 patients with distant metastases from differentiated thyroid cancer, poorly differentiated thyroid carcinoma, or anaplastic thyroid carcinoma. Targeted next-generation sequencing was performed with 50 known thyroid-cancer-related genes. Of the 82 tissues, 63 were from primary tumors and 19 from distant metastases. The most prevalent mutation observed from the primary tumors was TERT promoter mutation (56%), followed by BRAF (41%) and RAS (24%) mutations. TP3 was altered by 11%. Mutations in histone methyltransferases, SWI/SNF subunit-related genes, and PI3K/AKT/mTOR pathway-related genes were present in 42%, 12%, and 22%, respectively. When the mutational status was analyzed in 15 matched pairs of thyroid tumors and their matched distant metastases and one pair of distant metastases with two distinct sites, the concordance was high. A similar frequency of mutations in TERT promoter (58%) and BRAF (42%) as well as histone methyltransferases (37%), SWI/SNF subunits (10%), and PI3K/AKT/mTOR pathway (26%) were noted. The same main, early and late mutations were practically always present in individual primary tumor-metastasis pairs. Enrichment of TERT promoter, BRAF, and RAS mutations were detected in highly advanced thyroid cancers with distant metastasis. The genetic profiles of primary thyroid tumors and their corresponding distant metastases showed a high concordance.

Entities:  

Keywords:  advanced thyroid cancer; distant metastasis; genetic profile; next generation sequencing

Year:  2020        PMID: 32163911     DOI: 10.1530/ERC-19-0452

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  6 in total

1.  Loss of Integrase Interactor 1 (INI1) Expression in a Subset of Differentiated Thyroid Cancer.

Authors:  Kung-Chen Ho; Jie-Jen Lee; Chi-Hsin Lin; Ching-Hsiang Leung; Shih-Ping Cheng
Journal:  Diagnostics (Basel)       Date:  2020-05-05

Review 2.  Molecular Genetics of Follicular-Derived Thyroid Cancer.

Authors:  Elisabetta Macerola; Anello Marcello Poma; Paola Vignali; Alessio Basolo; Clara Ugolini; Liborio Torregrossa; Ferruccio Santini; Fulvio Basolo
Journal:  Cancers (Basel)       Date:  2021-03-07       Impact factor: 6.639

3.  Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: A matched case-control study.

Authors:  Linwah Yip; William E Gooding; Alyaksandr Nikitski; Abigail I Wald; Sally E Carty; Esra Karslioglu-French; Raja R Seethala; Dan P Zandberg; Robert L Ferris; Marina N Nikiforova; Yuri E Nikiforov
Journal:  Cancer       Date:  2021-02-04       Impact factor: 6.860

4.  2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.

Authors:  Keith C Bible; Electron Kebebew; James Brierley; Juan P Brito; Maria E Cabanillas; Thomas J Clark; Antonio Di Cristofano; Robert Foote; Thomas Giordano; Jan Kasperbauer; Kate Newbold; Yuri E Nikiforov; Gregory Randolph; M Sara Rosenthal; Anna M Sawka; Manisha Shah; Ashok Shaha; Robert Smallridge; Carol K Wong-Clark
Journal:  Thyroid       Date:  2021-03       Impact factor: 6.568

5.  The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer.

Authors:  Carla Colombo; Emanuela Minna; Chiara Gargiuli; Marina Muzza; Matteo Dugo; Loris De Cecco; Gabriele Pogliaghi; Delfina Tosi; Gaetano Bulfamante; Angela Greco; Laura Fugazzola; Maria Grazia Borrello
Journal:  J Exp Clin Cancer Res       Date:  2020-11-16

6.  Yield and costs of molecular diagnostics on thyroid cytology slides in the Netherlands, adapting the Bethesda classification.

Authors:  Mehtap Derya Aydemirli; Marieke Snel; Tom van Wezel; Dina Ruano; Christianne M H Obbink; Wilbert B van den Hout; Abbey Schepers; Hans Morreau
Journal:  Endocrinol Diabetes Metab       Date:  2021-09-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.